ConvaTec Group PLC Non-Executive Director appointment (5388M)
11 Maggio 2020 - 5:10PM
UK Regulatory
TIDMCTEC
RNS Number : 5388M
ConvaTec Group PLC
11 May 2020
Non-Executive Director appointment
Reading, United Kingdom (11 May 2020)
ConvaTec Group Plc ("ConvaTec" or "the Company") announces the
appointment of Heather Mason as a Non-Executive Director of the
Company with effect from 1 July 2020.
Heather has significant international healthcare experience
leading fully integrated global businesses. Previously she spent 27
years with Abbott Laboratories where she held a number of global
senior operational and strategic leadership roles, including Senior
Vice President of Abbott Diabetes Care and most recently Executive
Vice President of Abbot Nutrition. She retired from Abbot
Laboratories in 2017.
John McAdam, Chairman of ConvaTec, commented:
"I am very pleased to welcome Heather to our Board. She has deep
healthcare knowledge and brings very relevant international,
commercial and operational experience. In particular, as we
increase our focus on innovation to help drive our transformation,
her track record of overseeing the development of commercially
viable new product pipelines and brand building will be
invaluable."
Heather is currently a Non-Executive Director of Assertio
Therapeutics, Inc., the Nasdaq listed specialty pharmaceutical
company focused on providing responsible solutions to advance
patient care in the areas of neurology, orphan and speciality
medicines. She is also Co-Chair of the University of Michigan's
College of Engineering Innovation Committee and a member of its
Leadership Advisory Board.
No other information requires disclosure in accordance with
Listing Rule 9.6.13.
This announcement is made in accordance with Listing Rule
9.6.11R(1).
Enquiries:
Analysts and Investors
Mark Reynolds, Director Investor Relations +44 (0)7551 036
625
ir@convatec.com
Media
Buchanan: Charles Ryland/Chris Lane/Vicky Hayns +44 (0)207 466
5000
About ConvaTec
ConvaTec is a global medical products and technologies company
focused on therapies for the management of chronic conditions. The
Company is listed on the London Stock Exchange (stock symbol: CTEC)
and has established market positions in advanced wound care, ostomy
care, continence and critical care, and infusion care. ConvaTec's
products provide a range of clinical and economic benefits,
including infection prevention, protection of at-risk skin,
improved patient outcomes and reduced total cost of care.
www.convatecgroup.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAKKDBKPBKDAPD
(END) Dow Jones Newswires
May 11, 2020 11:10 ET (15:10 GMT)
Grafico Azioni Convatec (LSE:CTEC)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Convatec (LSE:CTEC)
Storico
Da Apr 2023 a Apr 2024